Literature DB >> 15271291

Cell surface receptors in lysophospholipid signaling.

Brigitte Anliker1, Jerold Chun.   

Abstract

The lysophospholipids, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), regulate various signaling pathways within cells by binding to multiple G protein-coupled receptors. Receptor-mediated LPA and S1P signaling induces diverse cellular responses including proliferation, adhesion, migration, morphogenesis, differentiation and survival. This review will focus on major components of lysophospholipid signaling: metabolism, identification and expression of LPA and S1P receptors, general signaling pathways and specific signaling mechanisms in mouse embryonic fibroblasts. Finally, in vivo effects of LP receptor gene deletion in mice will be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15271291     DOI: 10.1016/j.semcdb.2004.05.005

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  67 in total

1.  S1P activates store-operated calcium entry via receptor- and non-receptor-mediated pathways in vascular smooth muscle cells.

Authors:  Kristen Park Hopson; Jessica Truelove; Jerold Chun; Yumei Wang; Christian Waeber
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-26       Impact factor: 4.249

Review 2.  Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Authors:  Roger A Sabbadini
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 3.  Insights into the pharmacological relevance of lysophospholipid receptors.

Authors:  Tetsuji Mutoh; Richard Rivera; Jerold Chun
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 4.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

6.  A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.

Authors:  J S Swaney; C Chapman; L D Correa; K J Stebbins; R A Bundey; P C Prodanovich; P Fagan; C S Baccei; A M Santini; J H Hutchinson; T J Seiders; T A Parr; P Prasit; J F Evans; D S Lorrain
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

7.  Ovarian cancer-derived lysophosphatidic acid stimulates secretion of VEGF and stromal cell-derived factor-1 alpha from human mesenchymal stem cells.

Authors:  Eun Su Jeon; Soon Chul Heo; Il Hwan Lee; Yoon Ji Choi; Ji Hye Park; Kyung Un Choi; Do Youn Park; Dong Soo Suh; Man Soo Yoon; Jae Ho Kim
Journal:  Exp Mol Med       Date:  2010-04-30       Impact factor: 8.718

8.  Matrix-Assisted Laser Desorption Ionization Mapping of Lysophosphatidic Acid Changes after Traumatic Brain Injury and the Relationship to Cellular Pathology.

Authors:  Whitney S McDonald; Elizabeth E Jones; Jonathan M Wojciak; Richard R Drake; Roger A Sabbadini; Neil G Harris
Journal:  Am J Pathol       Date:  2018-07-16       Impact factor: 4.307

Review 9.  Lysophosphatidic acid and renal fibrosis.

Authors:  Jean-Philippe Pradère; Julien Gonzalez; Julie Klein; Philippe Valet; Sandra Grès; David Salant; Jean-Loup Bascands; Jean-Sébastien Saulnier-Blache; Joost P Schanstra
Journal:  Biochim Biophys Acta       Date:  2008-04-11

10.  Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Authors:  Ming Yan Xu; Joanne Porte; Alan J Knox; Paul H Weinreb; Toby M Maher; Shelia M Violette; Robin J McAnulty; Dean Sheppard; Gisli Jenkins
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.